Drugs / ZB001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05776121 | May 2023 → Apr 2024 | endocrine exophthalmos | Zenas BioPharma (USA), LLC | Completed | No outcome recorded |
| Phase 1 | NCT05542303 | Oct 2022 → Apr 2023 | — | Zenas BioPharma (USA), LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-08-01 | Zenas BioPharma (USA), LLC | Regulatory Zenas BioPharma Obtains IND Approval in China for Phase 1/2 Study of ZB001 for the Treatment of Thyroid Eye Disease zenasbio.com ↗ |
| 2022-05-16 | Zenas BioPharma (USA), LLC | Regulatory Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease zenasbio.com ↗
This study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZB001. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-08-01 | Zenas BioPharma (USA), LLC | Zenas BioPharma Obtains IND Approval in China for Phase 1/2 Study of ZB001 for the Treatment of Thyroid Eye Disease zenasbio.com ↗ |
| 2022-05-16 | Zenas BioPharma (USA), LLC | Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease zenasbio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZB001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05776121 ↗ |
| Modality | Monoclonal antibody | “humanized IgG1κ monoclonal antibody (mAb)” NCT05542303 ↗ |
| Route | Intravenous | “single IV injection” NCT05542303 ↗ |
| Target | IGF1R | “targeting human IGF-1R” NCT05776121 ↗ |